RU2756318C2 - Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) - Google Patents

Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) Download PDF

Info

Publication number
RU2756318C2
RU2756318C2 RU2017135605A RU2017135605A RU2756318C2 RU 2756318 C2 RU2756318 C2 RU 2756318C2 RU 2017135605 A RU2017135605 A RU 2017135605A RU 2017135605 A RU2017135605 A RU 2017135605A RU 2756318 C2 RU2756318 C2 RU 2756318C2
Authority
RU
Russia
Prior art keywords
ser
arg
tyr
asn
leu
Prior art date
Application number
RU2017135605A
Other languages
English (en)
Russian (ru)
Other versions
RU2017135605A (ru
RU2017135605A3 (https=
Inventor
Марлон Хиннер
Андреа Аллерсдорфер
Рачида Сихам Бел Айба
Михаэла АЛЁ
Александер Виденман
Габриеле МАЧИНЕР
Мартин Хюльсмейер
Original Assignee
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ filed Critical ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ
Publication of RU2017135605A publication Critical patent/RU2017135605A/ru
Publication of RU2017135605A3 publication Critical patent/RU2017135605A3/ru
Application granted granted Critical
Publication of RU2756318C2 publication Critical patent/RU2756318C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
RU2017135605A 2015-05-18 2016-05-18 Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) RU2756318C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15167922 2015-05-18
EP15167922.2 2015-05-18
PCT/EP2016/061058 WO2016184875A1 (en) 2015-05-18 2016-05-18 Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)

Publications (3)

Publication Number Publication Date
RU2017135605A RU2017135605A (ru) 2019-06-18
RU2017135605A3 RU2017135605A3 (https=) 2019-11-13
RU2756318C2 true RU2756318C2 (ru) 2021-09-29

Family

ID=53180583

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017135605A RU2756318C2 (ru) 2015-05-18 2016-05-18 Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)

Country Status (13)

Country Link
US (2) US10273275B2 (https=)
EP (1) EP3298029A1 (https=)
JP (2) JP6942060B2 (https=)
KR (1) KR20180008649A (https=)
CN (2) CN114456252A (https=)
AU (1) AU2016262838B2 (https=)
BR (1) BR112017020961A2 (https=)
CA (1) CA2982034A1 (https=)
MX (1) MX2017014730A (https=)
RU (1) RU2756318C2 (https=)
SG (1) SG11201707872WA (https=)
WO (1) WO2016184875A1 (https=)
ZA (1) ZA201706605B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
SG11201609274SA (en) 2014-05-22 2016-12-29 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
MX2021010039A (es) * 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007107563A2 (en) * 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
WO2012065978A1 (en) * 2010-11-15 2012-05-24 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2014076321A1 (en) * 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
ES2245780T3 (es) 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
DE4417598A1 (de) 1994-05-19 1995-12-14 Max Planck Gesellschaft Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
WO1998016873A1 (en) 1996-10-14 1998-04-23 Firm Forsat Ltd. Method for preparing dispersions of chromogenic components
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7235520B2 (en) 2000-09-21 2007-06-26 University Of Massachusetts Method of inducing apoptosis in lymphoid cells
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
CA2464690A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of apolipoprotein d
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
JP2007284351A (ja) 2004-07-27 2007-11-01 Osaka Bioscience Institute アミロイド蛋白質の凝集を抑制する物質とその作用
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2007137170A2 (en) 2006-05-20 2007-11-29 Seattle Genetics, Inc. Anti-glypican-3 antibody drug conjugates
US8313924B2 (en) 2006-08-01 2012-11-20 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
KR101570252B1 (ko) 2007-07-17 2015-11-19 메다렉스, 엘.엘.시. 글리피칸-3에 대한 단클론 항체
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
BR112012013662B1 (pt) * 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
US20130225505A1 (en) 2011-11-23 2013-08-29 Allergan, Inc. Muteins of human tear lipcalin for treating neovascular disease of the anterior segment of the human eye
JP6839087B2 (ja) 2015-01-28 2021-03-03 ピエリス ファーマシューティカルズ ゲーエムベーハー 血管新生に特異的な新規のタンパク質
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
KR102734408B1 (ko) 2015-05-04 2024-11-27 피어이스 파마슈티컬즈 게엠베하 Cd137에 특이적인 신규한 단백질
AU2016262838B2 (en) 2015-05-18 2020-10-08 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2395519C2 (ru) * 2005-08-09 2010-07-27 Онкотерапи Сайенс, Инк. Глипикан-3 (gpc3)-производные антигенные пептиды, отторгающие опухоли, используемые для нla-a2-положительных пациентов, и фармацевтическая продукция, включающая их
WO2007107563A2 (en) * 2006-03-20 2007-09-27 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
WO2012065978A1 (en) * 2010-11-15 2012-05-24 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
WO2014076321A1 (en) * 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARNAU J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13. *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581; *
FRANKEL A.E. et al., Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor, Protein Eng., 2000, v.13, n.8, p.575-581; ORLANDO M., Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES), Inauguraldissertation, Giesen, 2003, p.166; ARNAU J. et al., Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins, Protein expression and purification, 2006, V. 48, N. 1, p.1-13. *
ORLANDO M., Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES), Inauguraldissertation, Giesen, 2003, p.166; *
WU Н. et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, J. Mol. Biol, 1999, Vol. 294, pp. 151-162 *
WU Н. et al., Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues, J. Mol. Biol, 1999, Vol. 294, pp. 151-162; *

Also Published As

Publication number Publication date
RU2017135605A (ru) 2019-06-18
JP6942060B2 (ja) 2021-09-29
US10273275B2 (en) 2019-04-30
RU2017135605A3 (https=) 2019-11-13
JP2018519802A (ja) 2018-07-26
KR20180008649A (ko) 2018-01-24
EP3298029A1 (en) 2018-03-28
WO2016184875A1 (en) 2016-11-24
US20180141988A1 (en) 2018-05-24
AU2016262838A1 (en) 2018-01-04
BR112017020961A2 (pt) 2018-07-10
MX2017014730A (es) 2018-06-28
CN107787327A (zh) 2018-03-09
ZA201706605B (en) 2020-05-27
CA2982034A1 (en) 2016-11-24
JP7217783B2 (ja) 2023-02-03
AU2016262838B2 (en) 2020-10-08
US20190309037A1 (en) 2019-10-10
CN114456252A (zh) 2022-05-10
SG11201707872WA (en) 2017-10-30
JP2021184725A (ja) 2021-12-09
US10787491B2 (en) 2020-09-29
CN107787327B (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
RU2756318C2 (ru) Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3)
EP2640740B1 (en) Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
RU2515063C2 (ru) Мутеины липокалина слезной жидкости, обладающие аффинностью к с-мет рецепторной тирозинкиназе человека и способы их получения
CN103038249B (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
JP6843754B2 (ja) ピオベルジン及びピオケリンに特異的な新規なタンパク質
EP2990798B1 (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target